- Conditions
- Clostridium Difficile-associated Diarrhea (CDAD)
- Interventions
- Fidaxomicin oral suspension, Fidaxomicin tablets, Vancomycin oral liquid, Vancomycin capsules
- Drug
- Lead sponsor
- Astellas Pharma Europe B.V.
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 14
- States / cities
- Orange, California • Chicago, Illinois • Indianapolis, Indiana + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Moderate Clostridium Difficile Infection
- Interventions
- LFF571, Vancomycin (POC)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 14
- States / cities
- Palm Desert, California • Bristol, Connecticut • Clearwater, Florida + 11 more
- Conditions
- Clostridium Difficile Infection
- Interventions
- Cadazolid, Vancomycin, Placebo-matching cadazolid, Placebo-matching vancomycin
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 11
- States / cities
- Newark, Delaware • Jacksonville, Florida • Orlando, Florida + 8 more
- Conditions
- Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
- Interventions
- Oral Vancomycin, Placebo
- Drug · Other
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Tampa, Florida
- Conditions
- Healthy Volunteers
- Interventions
- VE303, Oral Vancomycin
- Drug
- Lead sponsor
- Vedanta Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Primary Sclerosing Cholangitis, Post- Orthotopic Liver Transplantation
- Interventions
- Vancomycin
- Drug
- Lead sponsor
- Ochsner Health System
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Impaired Hepatic Function
- Interventions
- eravacycline
- Drug
- Lead sponsor
- Tetraphase Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 3
- States / cities
- Lakewood, Colorado • Orlando, Florida • Knoxville, Tennessee
- Conditions
- Clostridioides Difficile, Vancomycin Resistance Enterococcus Faecium
- Interventions
- Vancomycin (POC)
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 65 Years to 100 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2027
- U.S. locations
- 1
- States / cities
- Glen Burnie, Maryland
- Conditions
- Clostridium Difficile Infection
- Interventions
- Fecal microbiota transplant G3 capsules, Oral Vancomycin alone
- Biological · Other
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Infections, Pediatrics
- Interventions
- Ceftaroline fosamil, Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam, Cephalexin or Clindamycin or Linezolid
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 2 Months to 17 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Orange, California • San Diego, California + 23 more
- Conditions
- Clostridium Difficile Infection
- Interventions
- Cadazolid, Vancomycin capsule, Vancomycin solution
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- Idaho Falls, Idaho • Chicago, Illinois • Shreveport, Louisiana + 2 more
- Conditions
- Osteomyelitis, Methicillin-resistant Staphylococcus Aureus
- Interventions
- trimethoprim-sulfamethoxazole, vancomycin
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Clostridium Difficile Infection Recurrence
- Interventions
- FMT oral capsule, Oral Vancomycin, FMT oral placebo, Oral Vancomycin placebo
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Rochester, Minnesota + 2 more
- Conditions
- Clostridioides Difficile Infection
- Interventions
- CRS3123, Active Comparator
- Drug
- Lead sponsor
- Crestone, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 18
- States / cities
- Fullerton, California • Lancaster, California • Mission Hills, California + 14 more
- Conditions
- Intestinal Multi-drug Resistant Organism Colonization
- Interventions
- Microbiome Therapeutic, Placebo
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Johns Creek, Georgia
- Conditions
- Cystic Fibrosis
- Interventions
- Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Cleveland, Ohio
- Conditions
- Crohn's Disease
- Interventions
- Fluconazole, Vancomycin, Neomycin, Ciprofloxacin, Polyethylene Glycol 3350, Promethazine, Fluconazole placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hematopoietic Stem Cell Transplantation (HSCT), Acute GVH Disease
- Interventions
- Vancomycin-polymyxin B
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 4 Years to 30 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Autism Spectrum Disorder, Gastro-Intestinal Disorder, Constipation, Diarrhea
- Interventions
- MTP-101P, Vancomycin, Miralax, Antacid, Placebo MTP-101P, Placebo Vancomycin
- Combination Product
- Lead sponsor
- Gut-Brain-Axis Therapeutics Inc.
- Other
- Eligibility
- 4 Years to 18 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Oral Vancomycin
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
- Interventions
- Bezlotoxumab, Standard CDI treatment
- Biological · Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
- Conditions
- Clostridium Difficile Infection, Vancomycin Resistant Enterococci Infection
- Interventions
- Vancomycin 125mg, Placebo
- Drug
- Lead sponsor
- Riverside University Health System Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Moreno Valley, California
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
- Interventions
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Daniel Benjamin
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 3,520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 43
- States / cities
- Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
- Conditions
- Metastatic Cancer, Melanoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer
- Interventions
- VE800, Nivolumab, Vancomycin Oral Capsule
- Biological · Drug
- Lead sponsor
- Vedanta Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 13 more